News | September 09, 2013

Medtronic Forms Hospital Solutions Business Aimed at Driving Efficiencies and Cost Savings

Medtronic Hospital Solutions Signs First Contracts with Two Hospitals in Europe

September 9, 2013 — Medtronic Inc. has formed Medtronic Hospital Solutions, a new business focused on developing novel partnerships with hospitals to provide services directly related to hospital operational efficiency. The new business will focus initially on offering services in Europe to manage and modernize catheterization laboratory (cath lab) facilities, bringing sustainable efficiencies and programs to this critical area of hospital cardiology departments.

Medtronic Hospital Solutions also has announced it was awarded its first tenders with two leading hospitals in Europe. These two long-term tenders have been awarded to Medtronic to manage cath lab facilities for the University Hospital of South Manchester (UHSM) NHS Trust and Imperial College Healthcare NHS Trust in London. Medtronic will manage these hospitals’ cath labs to high standards, providing the latest medical technology and infrastructure, optimizing operational efficiency, running daily operations and developing local cardiac services markets, including the care pathway for patients who need access to cardiac care. Medtronic will administer four UHSM cath labs at Wythenshawe Hospital and five Imperial College Healthcare cath labs based at Hammersmith Hospital.  

Through the Hospital Solutions business, Medtronic will collaborate with hospitals to create efficiencies by offering a suite of tools and process models that help healthcare providers to improve the quality and efficiency of their service delivery, including ensuring affordable access to the latest technologies and treatment options. These efforts will also address and expand patient care pathways, potentially increasing access to care for patients.  This is at a time when hospitals and health systems are being challenged to meet the demands of an aging population.

In a pilot program conducted last year where Medtronic provided similar hospital efficiency solutions, Maastricht University Medical Center in The Netherlands estimated it had saved an estimated $6 million USD in one year. During this time Medtronic provided on-site program management to help with hospital staff training, embedding a performance improvement culture, and driving improvements in efficiency, quality, clinical outcomes and patient experience.

For more information: www.medtronic.com

 

Related Content

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major